Xenon-2026-JPM.pdf

1、NASDAQ:XENExenon-Corporate Overview2026 J.P.MORGAN HEALTHCARE CONFERENCEJANUARY 2026Forward Looking Statement/Safe HarborThis slide presentation and the accompanying oral commentary contain forward-looking statements(within the meaning of Section 27A of the Securities Act of 1933,as amended,and Sect

2、ion 21E of the Securities Exchange Act of 1934,as amended,and the Private Securities Litigation Reform Act of 1995 and Canadian Securities laws)that involve risks,uncertainties and assumptions.If the risks or uncertainties ever materialize or the assumptions prove incorrect,our results may differ ma

3、terially from those expressed or implied by such forward-looking statements.All statements other than statements of historical fact could be deemed forward-looking and include statements regarding the timing of and potential results from clinical studies;the potential efficacy,safety profile,future

4、development plans in current and anticipated indications,addressable market,regulatory success and commercial potential of our and our partners product candidates;the efficacy of our clinical study designs;our ability to successfully develop and achieve milestones in our azetukalner and other pipeli

5、ne and development programs,including the anticipated filing of INDs and NDAs;the timing and results of our interactions with regulators,including the timing of any NDA submission;our ability to successfully develop and obtain regulatory approval of azetukalner and our other product candidates;antic

6、ipated timing of topline data readout from our clinical studies of azetukalner;and our expectation that we will have sufficient cash to fund operations into 2027.These forward-looking statements are based on current assumptions that involve risks,uncertainties and other factors that may cause the ac